Cargando…

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

BACKGROUND: The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC). METHODS: First, miRNA expression profiles were determined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevic, Ines, Müller, Volkmar, Weber, Karsten, Fasching, Peter A., Karn, Thomas, Marmé, Frederic, Schem, Christian, Stickeler, Elmar, Denkert, Carsten, van Mackelenbergh, Marion, Salat, Christoph, Schneeweiss, Andreas, Pantel, Klaus, Loibl, Sibylle, Untch, Michael, Schwarzenbach, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178264/ https://www.ncbi.nlm.nih.gov/pubmed/30301470 http://dx.doi.org/10.1186/s12916-018-1163-y

Ejemplares similares

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019)

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
por: Rüger, Alexandra Maria, et al.
Publicado: (2020)

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
por: Fasching, Peter A., et al.
Publicado: (2023)

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019)

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
por: Stürken, Christine, et al.
Publicado: (2021)

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
por: Stürken, Christine, et al.
Publicado: (2021)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
por: Wimberger, Pauline, et al.
Publicado: (2023)

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
por: Schneeweiss, Andreas, et al.
Publicado: (2021)

Sixto Adalberto Tejeda Olivares
por: García Morales, Soledad
Publicado: (1973)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

La muerte de Sixto y otros cuentos
por: García Medina, Heriberto
Publicado: (1966)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2018)

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
por: Pan, Chi, et al.
Publicado: (2018)

Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2019)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
por: Reinisch, Mattea, et al.
Publicado: (2022)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

Deep phenotyping as a contribution to personalized depression therapy: the GEParD and DaCFail protocols
por: Lichter, Katharina, et al.
Publicado: (2023)

Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
por: Untch, Michael, et al.
Publicado: (2023)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
por: Denkert, Carsten, et al.
Publicado: (2023)

Interplay of lncRNA H19/miR‐675 and lncRNA NEAT1/miR‐204 in breast cancer
por: Müller, Volkmar, et al.
Publicado: (2019)

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
por: Lux, Michael P., et al.
Publicado: (2021)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_d47fof4j3bede7so2ldhmhv3ok